Physician profile
Kevin Weber
NPI 1417967563
$287.67
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $93.74 · 2021: $15.21.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.55 | 2019 | |
| Pfizer INC. | $40.54 | 2019-2020 | |
| Novo Nordisk INC | $26.49 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $24.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.98 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.80 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.01 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.76 | 2019 | |
| Merck Sharp & Dohme LLC | $15.21 | 2021 | |
| Amarin Pharma, INC. | $13.81 | 2020 | |
| Mylan Specialty L.P. | $13.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.28 | 2019 | |
| Astellas Pharma US INC | $11.83 | 2019 | |
| Glaxosmithkline, LLC. | $11.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.